Phase II Study With Cabozantinib in Patients With RET Positive NSCLC

NCT04131543 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG: Cabozantinib 20 MG
DRUG: Cabozantinib 40 MG
DRUG: Cabozantinib 60 MG

Sponsor

University of Bologna

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]